S100A7, a Novel Alzheimer's disease biomarker with non-amyloidogenic α-secretase activity acts via selective promotion of ADAM-10

PLoS ONE

Volumn 4, Issue 1, 2009, Pages

  Qin, Weiping ^a   Ho, Lap ^a,b   Wang, Jun ^a,b   Peskind, Elaine ^c   Pasinetti, Giulio Maria ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM 10 PROTEIN; ADAM PROTEIN; ALPHA SECRETASE; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; MESSENGER RNA; PSORIASIN; UNCLASSIFIED DRUG; ADAM10 PROTEIN, HUMAN; AMYLOID; CALCIUM BINDING PROTEIN; MEMBRANE PROTEIN; PEPTIDE; S100A7 PROTEIN, HUMAN; SECRETASE;

ADENOVIRUS; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; BRAIN CORTEX; BRAIN NERVE CELL; BRAIN TISSUE; CONTROLLED STUDY; EARLY DIAGNOSIS; EMBRYO; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION SYSTEM; HIPPOCAMPUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IN VITRO STUDY; MASS SPECTROMETRY; MOUSE; NEUROPATHOLOGY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PURIFICATION; PROTEOMICS; SEQUENCE ANALYSIS; SURFACE ENHANCED LASER DESORPTION IONIZATION MASS SPECTROMETRY; ANIMAL; BLOOD; CASE CONTROL STUDY; CHEMISTRY; CHO CELL; CRICETULUS; HAMSTER; METABOLISM; THROMBOCYTE;

MUS MUSCULUS;

ADAM PROTEINS; ALZHEIMER DISEASE; AMYLOID; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BIOLOGICAL MARKERS; BLOOD PLATELETS; CALCIUM-BINDING PROTEINS; CASE-CONTROL STUDIES; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; MEMBRANE PROTEINS; PEPTIDES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 58449133739     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004183     Document Type: Article

References (41)

1. National Institute on Aging, Alzheimer's Disease Education & Referral Center. Prevalence and Costs of Alzheimer's Disease. Available at http://www.alzheimers.org/pubs/pr97.html#intro. Accessed April 230, 2005.
2. Bussiere T, Giannakopoulos P, Bouras C, Perl DP, Morrison JH, et al. (2003) Progressive degeneration of nonphosphorylated neurofilament protein-enriched pyramidal neurons predicts cognitive impairment in Alzheimer's disease: stereologic analysis of prefrontal cortex area 9. J Comp Neurol 463: 281-302.
3. Thompson PM, Hayashi KM, De Zubicaray GI, Janke AL, Rose SE, et al. (2004) Mapping hippocampal and ventricular change in Alzheimer disease. Neuroimage 22: 1754-1766.
4. Takeuchi M, Sato T, Takino J, Kobayashi Y, Furuno S, et al. (2007) Diagnostic utility of serum or cerebrospinal fluid levels of toxic advanced glycation endproducts (TAGE) in early detection of Alzheimer's disease. Med Hypotheses 69: 1358-1366.
5. Ward M (2007) Biomarkers for Alzheimer's disease. Expert Rev Mol Diagn 7: 635-646.
6. Keating CD (2005) Nanoscience enables ultrasensitive detection of Alzheimer's biomarker. Proc Natl Acad Sci USA 102: 2263-2264.
7. Leuner K, Pantel J, Frey C, Schindowski K, et al. (2007) Enhanced apoptosis, oxidative stress and mitochondrial dysfunction in lymphocytes as potential biomarkers for Alzheimer's disease. J Neural Transm Suppl 72: 207-215.
8. Bosman GJ, Bartholomeus IG, de Man AJ, van Kalmthout PJ, de Grip WJ (1991) Erythrocyte membrane characteristics indicate abnormal cellular aging in patients with Alzheimer's disease. Neurobiol Aging 12: 13-18.
9. Pirttilä T, Mattinen S, Frey H (1992) The decrease of CD8-positive lymphocytes in Alzheimer's disease. J Neurol Sci 107: 160-165.
10. Ghanbari H, Ghanbari K, Beheshti I, Munzar M, Vasauskas A, et al. (1998) Biochemical assay for AD7C-NTP in urine as an Alzheimer's disease marker. J Clin Lab Anal 12: 285-288.
11. Bonafé JL, Cambon L, Ousset PJ, Pech JH, Bellet H, et al. (1998) Abnormal hair samples from patients with Alzheimer disease. Arch Dermatol 134: 1300.
12. Heinonen O, Soininen H, Syrjänen S, Neittaanmäki H, Paljärvi L, et al. (1994) β-amyloid protein immunoreactivity in skin is not a reliable marker of Alzheimer's disease. An autopsy-controlled study. Arch Neurol 51: 799-804.
13. Selkoe DJ, Schenk D (2003) Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 43: 545-584.
14. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, et al. (1989) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39: 1159-1165.
15. Mobbs CV, Yen K, Mastaitis J, Nguyen H, Watson E, et al. (2004) Mining microarrays for metabolic meaning: nutritional regulation of hypothalamic gene expression. Neurochem Res 29: 1093-1103.
16. Johnson V, Byington RE (1990) Quantitative assays for virus infectivity. In Aldovini A, Walker BD, eds. Techniques in HIV Research. New York: Stockton Press. pp 71-76.
17. Nyberg-Hoffman C, Shabram P, Li W, Giroux D, Aguilar-Cordova E (1997) Sensitivity and reproducibility in adenoviral infectious titer determination. Nat Med 3: 808-811.
18. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 65: 55-63.
19. Kelley KA, Ho L, Winger D, Freire-Moar J, Borelli CB, et al. (1999) Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2. Am J Pathol 155: 995-1004.
20. McLendon C, Xin T, Ziani-Cherif C, Murphy MP, Findlay KA, et al. (2000) Cell-free assays for gamma-secretase activity. FASEB J 14: 2383-2386.
21. Pinnix I, Musunuru U, Tun H, Sridharan A, Golde T, et al. (2001) A novel gamma -secretase assay based on detection of the putative C-terminal fragmentgamma of amyloid beta protein precursor. J Biol Chem 276: 481-487.
22. Sastre M, Steiner H, Fuchs K, Capell A, Multhaup G, et al. (2001) Presenilindependent gamma-secretase processing of beta-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO Rep 2: 835-841.
23. Qin W, Ho L, Pompl PN, Peng Y, Zhao Z, et al. (2003) Cyclooxygenase (COX)-2 and COX-1 potentiate beta-amyloid peptide generation through mechanisms that involve gamma-secretase activity. J Biol Chem 278: 50970-50977.
24. Flanagan JG, Leder P (1990) The kit ligand: a cell surface molecule altered in steel mutant fibroblasts. Cell 63: 185-194.
25. Cheng HJ, Flanagan JG (2001) Cloning and characterization of RTK ligands using receptor-alkaline phosphatase fusion proteins. Methods Mol Biol 124: 313-334.
26. Watson PH, Leygue ER, Murphy LC (1998) Psoriasin (S100A7). Int J Biochem Cell Biol 30: 567-571.
27. Burns M, Gaynor K, Olm V, Mercken M, LaFrancois J, et al. (2003) Presenilin redistribution associated with aberrant cholesterol transport enhances betaamyloid production in vivo. J Neurosci 23: 5645-5649.
28. Postina R, Schroeder A, Dewachter I, Bohl J, Schmitt U, et al. (2004) A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest 113: 1456-1464.
29. Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, et al. (1999) Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA 96: 3922-3927.
30. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, et al. (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274: 99-102.
31. Allinson TM, Parkin ET, Condon TP, Schwager SL, Sturrock ED, et al. (2004) The role of ADAM10 and ADAM17 in the ectodomain shedding of angiotensin converting enzyme and the amyloid precursor protein. Eur J Biochem 271: 2539-2547.
32. Mills J, Reiner PB (1999) Mitogen-activated protein kinase is involved in Nmethyl- D-aspartate receptor regulation of amyloid precursor protein cleavage. Neuroscience 94: 1333-1338.
33. Mills J, Laurent Charest D, Lam F, Beyreuther K, et al. (1997) Regulation of amyloid precursor protein catabolism involves the mitogen-activated protein kinase signal transduction pathway. J Neurosci 17: 9415-9422.
34. Desdouits-Magnen J, Desdouits F, Takeda S, Syu LJ, Saltiel AR, et al. (1998) Regulation of secretion of Alzheimer amyloid precursor protein by the mitogenactivated protein kinase cascade. J Neurochem 70: 524-530.
35. Colciaghi F, Borroni B, Pastorino L, Marcello E, Zimmermann M, et al. (2002) [alpha]-Secretase ADAM10 as well as [alpha]APPs is reduced in platelets and CSF of Alzheimer disease patients. Mol Med 8: 67-74.
36. Steinerman JR, Honig LS (2007) Laboratory biomarkers in Alzheimer's disease. Curr Neurol Neurosci Rep 7: 381-387.
37. Rifai N, Gillette MA, Carr SA (2006) Protein biomarker discovery and validation: The long and uncertain path to clinical utility. Nat Biotechnol 24: 971-983.
38. Asai M, Hattori C, Szabo B, Sasagawa N, Maruyama K, et al. (2003) Putative function of ADAM9, ADAM10, and ADAM17 as APP alpha-secretase. Biochem Biophys Res Commun 301: 231-235.
39. Lee HG, Zhu X, Nunomura A, Perry G, Smith MA (2006) Amyloid Beta: the alternative hypothesis. Curr Alzheimer Res 3: 75-80.
40. Castellani RJ, Lee HG, Zhu X, Nunomura A, Perry G, et al. (2006) Neuropathology of Alzheimer's disease: pathognomonic but not pathogenic. Acta Neuropathol 111: 503-509.
41. Gustaw KA, Garrett MR, Lee HG, Castellani RJ, Zagorski MG, et al. (2008) Antigen-antibody dissociation in Alzheimer disease: a novel approach to diagnosis. J Neurochem 106: 1350-1356.